Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report

Vardah Gill

Wed, May 20, 2026 at 7:49 AM EDT 2 min read

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 10 Best Long Term Low Risk Stocks to Buy According to Hedge Funds.

On May 10, Morgan Stanley lowered its price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $168 from $175. It reiterated an Overweight rating on the shares. The firm updated its model for the company following the first-quarter earnings report.

On May 8, Truist lifted its price goal on GILD to $157 from $155. It kept a Buy rating on the stock. The analyst said the company delivered first-quarter revenue and earnings results above expectations and also raised its FY26 revenue guidance. According to the research note, the performance was driven by strength in the HIV business, especially Yeztugo. The firm also highlighted management’s comments around early persistence signals. It noted that Yeztugo showed the highest persistence among patients receiving re-treatment in the PrEP setting. Truist described those trends as encouraging and said they remain central to its view that Yeztugo can achieve durable growth toward a potential $7B-plus peak revenue opportunity.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on developing medicines to prevent and treat life-threatening diseases. Its areas of focus include HIV, viral hepatitis, COVID-19, cancer, and inflammation.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Dividend Penny Stocks to Buy Right Now and 11 Best Long Term US Stocks to Buy Right Now

Disclosure: None. Follow Insider Monkey on Google News.